Skip to main content

Table 1 Demographic features and cognitive performance of patients with aMCI due to AD, MCI due to FTLD, AD dementia and FTLD dementia

From: CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis

 

SCD (n = 33)

AD-aMCI (n = 109)

AD dementia (n = 67)

FTLD-MCI (n = 25)

FTLD dementia (n = 29)

Demographics

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Age

68.50 ± 12.03

71.30 ± 8.00 d, e

70.60 ± 8.62 d, e

65.50 ± 6.25 b, c,e

66.00 ± 7.56 b, c,d

Sex (female/male)

17/16

66/43

46/21 d

11/14 c

14/15

Years of education

15.97 ± 3.11 c, e

14.70 ± 3.28 c

13.60 ± 2.68 a, b

14.40 ± 2.89

14.00 ± 2.68 a

APOE ε4 carriers, n (%)

27% (9) b, c

53% (58) a, d,e

59% (40) a, d,e

24% (6) b, c,e

27% (8) b,c, d

CSF Neurogranin (pg/mL)

174.06 ± 61.09 b, c

232.94 ± 96.30 a, d

259.93 ± 109.61 a, d,e

161.45 ± 72.15 b, c,e

208.80 ± 102.56 c, d

CSF Aβ1−42/Neurogranin ratio

4.21 ± 1.51 b, c

2.47 ± 1.72 a, c,d

1.88 ± 1.14 a, b,e

5.10 ± 1.39 b, e

4.48 ± 1.39 c, d

CSF Aβ1−42 (pg/mL)

721.70 ± 388.46 b, c

492.51 ± 302.36 a, d,e

426.66 ± 232.11 a, d,e

779.10 ± 321.85 b, c,e

736.15 ± 242.96 b, c,d

1−42/1−40 ratio

0.07 ± 0.02 b, c

0.05 ± 0.02 a, d,e

0.04 ± 0.01 a, d,e

0.08 ± 0.02 b, c,e

0.07 ± 0.02 b, c,d

CSF Aβ1−40 (pg/mL)

9668.13 ± 3390.06

10086.48 ± 3585.11

9528.48

8601.96 ± 3943.75

8846.86 ± 2713.00

CSF p-tau 181 (pg/mL)

38.64 ± 15.39 b, c,e

86.23 ± 54.61 a, c,d

107.67 ± 65.36 a, b,d, e

37.33 ± 17.59 b, c,e

76.20 ± 69.52 a, c,d

CSF t-tau (pg/mL)

276.63 ± 101.71 b, c,e

569.06 ± 345.44 a, c,d

712.46 ± 419.80 a, b,d

308.72 ± 141.60 b, c

563.41 ± 419.56 a

Serum NfL (pg/mL)

45.40 ± 38.00 e

33.88 ± 27.78 e

41.59 ± 28.81 e

47.94 ± 48.31 e

63.37 ± 51.40 a, b,c, d

Cognitive Performance

 

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

MMSE score

29.03 ± 1.00 b, c,d, e

24.80 ± 2.87 a, c,e

18.50 ± 4.12 a, b,d, e

26.00 ± 3.42 a, c,e

21.20 ± 5.93 a, b,c, d

LOG-I

14.47 ± 4.58 b, c,d, e

8.69 ± 4.34 a, c,e

4.20 ± 3.33 a, b,d, e

9.74 ± 3.77 a, c,e

6.14 ± 2.80 a, b,c, d

LOG-D

13.28 ± 4.43 b, c,d, e

4.96 ± 5.08 a, c

1.16 ± 2.00 a, b,d, e

6.32 ± 5.46 a, c,e

3.90 ± 3.18 a, c,d

ROCF-R

15.28 ± 6.62 b, c,d, e

8.49 ± 6.28 a, c

2.47 ± 2.67 a, b,d, e

11.07 ± 6.07 a, c,e

6.66 ± 7.78 a, c,d

F-DigitSpan-SC

8.93 ± 1.57 b, c,d, e

8.04 ± 2.12 a, c,e

6.86 ± 2.05 a, b

7.80 ± 2.35 a

6.50 ± 2.55 a, b

B-DigitSpan-SC

6.37 ± 1.85 b, c,d, e

5.06 ± 1.95 a, c,e

3.65 ± 1.91 a, b,d

4.76 ± 2.01 a, c

3.92 ± 2.22 a, b

TMT-A

44.40 ± 18.08 b, c,d, e

58.50 ± 29.43 a, c,e

107.00 ± 55.91 a, b,d

61.10 ± 32.82 a, c

84.12 ± 59.60 a, b

TMT-B

116.42 ± 56.25 b, c,d, e

177.08 ± 81.92 a, c,e

246.04 ± 84.02 a, b,d

183.70 ± 82.22 a, c

234.51 ± 80.18 a, b

P-VF

43.5 ± 10.54 b, c,d, e

34.07 ± 13.00 a, c,d, e

24.42 ± 9.82 a, b,e

21.76 ± 10.58 a, b,e

15.39 ± 11.14 a, b,c, d

BNT-30

2.93 ± 2.84 b, c,d, e

6.00 ± 4.22 a, c,d, e

10.93 ± 5.96 a, b

8.89 ± 6.04 a, b

11.10 ± 5.89 a, b

S-VF-A

23.4 ± 6.16 b, c,d, e

16.24 ± 5.61 a, c,d, e

11.02 ± 5.77 a, b

12.83 ± 5.78 a, b

8.44 ± 5.58 a, b

CDT

14.79 ± 1.57 b, c,e

12.69 ± 3.45 a, e

9.31 ± 3.90 a, b,d

14.18 ± 1.70 c

10.74 ± 4.21 a, b

ROCF-C

29.29 ± 4.40 b, c,e

26.15 ± 7.30 a

15.33 ± 10.56 a, b,d, e

28.40 ± 6.07 c, e

22.81 ± 10.42 a, c,d

  1. Data are expressed as mean ± standard deviation, except for sex and APOE ε4 carrier status. P-values are comparisons using t-test for continuous variables and chi square test for categorical variables
  2. Abbreviations AD, Alzheimer’s disease; FTLD, frontotemporal lobar degeneration; aMCI, amnestic mild cognitive impairment; MCI, mild cognitive impairment; SCD, subjective cognitive decline; APOE, apolipoprotein E; MMSE, Mini Mental State Examination, total score; LOG-I, Logical Memory Immediate Recall; LOG-D, Logical Memory Delayed Recall; ROCF-R, Rey-Osterrieth Complex Figure, visual reproduction after 3 min; F-DigitSpan-SC, forward Digit Span - score; B-DigitSpan-SC, backward Digit Span - score; TMT-A, Trail Making Test A, given in seconds; TMT-B, given in seconds; P-VF, Phonemic Verbal Fluency; BNT-30, Boston Naming Test, 30 odd-items version, errors after a semantic cue; S-VF-A, Semantic Verbal Fluency - Animals; CDT- Clock Drawing Test, score; ROCF-C, copy condition score
  3. a Indicates statistically significant differences (p < .05) between SCD and other diagnostic subgroups
  4. bp < 0.05 versus AD-aMCI
  5. cp < 0.05 versus AD dementia
  6. dp < 0.05 versus FTLD-MCI
  7. ep < 0.05 versus FTLD dementia